Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | MRD: decision making in CLL

Susan O’Brien • 1 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Venetoclax

MRD offers a huge advantage in the development of prognostics in chronic lymphocytic leukemia (CLL), but how does the technique impact decision making in the clinical environment? Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses this at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Susan O’Brien

2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals